A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

December 10, 2019

Study Completion Date

August 30, 2023

Conditions
Solid Tumor
Interventions
DRUG

LY3321367

Administered IV

DRUG

LY3300054

Administered IV

Trial Locations (15)

10032

Columbia University College of Phys & Surgeons, New York

10065

Memorial Sloan Kettering Cancer Center, New York

28040

Fundación Jiménez Díaz-Oncology, Madrid

28050

Hospital Madrid Norte Sanchinarro, Madrid

29010

Hospital Clinico Universitario Virgen de la Victoria, Málaga

37203

Sarah Cannon Research Institute SCRI, Nashville

73104

Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City

77030

University of Texas MD Anderson Cancer Center, Houston

78229

The START Center for Cancer Care, San Antonio

85719

The University of Arizona Cancer Center, Tucson

02215

Dana Farber Cancer Institute, Boston

277 8577

National Cancer Center Hospital East, Kashiwa

104-0045

National Cancer Center Hospital, Chuo-Ku

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03099109 - A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors | Biotech Hunter | Biotech Hunter